Vismodegib + FAK Inhibitor GSK2256098 + Capivasertib + Abemaciclib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intracranial Meningioma
Conditions
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Trial Timeline
Sep 28, 2015 → Jan 1, 2028
NCT ID
NCT02523014About Vismodegib + FAK Inhibitor GSK2256098 + Capivasertib + Abemaciclib
Vismodegib + FAK Inhibitor GSK2256098 + Capivasertib + Abemaciclib is a phase 2 stage product being developed by Brain Biotech for Intracranial Meningioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02523014. Target conditions include Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02523014 | Phase 2 | Recruiting |
Competing Products
6 competing products in Intracranial Meningioma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tirzepatide + Tirzepatide Placebo | Eli Lilly | Approved | 85 |
| Ticagrelor + Aspirin + Rivaroxaban + Aspirin + Clopidogrel + Aspirin | AstraZeneca | Phase 3 | 77 |
| cabazitaxel + lapatinib | Novartis | Phase 2 | 52 |
| Everolimus + Bevacizumab | Novartis | Phase 2 | 52 |
| [177Lu]Lu-DOTATATE | Novartis | Phase 2 | 52 |
| Methylprednisolone (Injectable Form) + Placebo Injection | Brain Biotech | Approved | 77 |